Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Ritu Baral reiterated a Buy rating on Palvella Therapeutics (PVLA) with a $267 price target. Baral, a top 100 analyst, covers the healthcare sector. The stock currently holds a Strong Buy consensus among analysts, with an average price target of $235.40.
In a report released today, Ritu Baral from TD Cowen reiterated a Buy rating on Palvella Therapeutics, with a price target of $267.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Baral is a top 100 analyst with an average return of 44.2% and a 54.84% success rate. Baral covers the Healthcare sector, focusing on stocks such as Insmed, Palvella Therapeutics, and Atai Beckley N.V..
Palvella Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $235.40.